Multifunctional delivery strategies and nanoplatforms of SN-38 in cancer therapeutics
Authors:
- 7 June 2025
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 384, 113937
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30CA240139)
- Leonard M. Miller School of Medicine, University of Miami
- National Institutes of Health
- University of Miami
This publication has 163 references indexed in Scilit:
- Tumor‐Activatable Nanoparticles Target Low‐Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor EfficacyAdvanced Science, 2022
- Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub‐5 Ultrafine Iron Oxide NanoparticlesAdvanced Healthcare Materials, 2022
- Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancerInvestigational New Drugs, 2022
- Nanoparticulation of Prodrug into Medicines for Cancer TherapyAdvanced Science, 2021
- Solutions to the Drawbacks of Photothermal and Photodynamic Cancer TherapyAdvanced Science, 2021
- PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activityCancer Chemotherapy and Pharmacology, 2019
- Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograftCancer Chemotherapy and Pharmacology, 2019
- Solubility‐Improved 10‐O‐Substituted SN‐38 Derivatives with Antitumor ActivityChemMedChem, 2017
- Self‐Assembling Prodrugs by Precise Programming of Molecular Structures that Contribute Distinct Stability, Pharmacokinetics, and Antitumor EfficacyAdvanced Functional Materials, 2015
- Camptothecin and taxol: Discovery to clinicMedicinal Research Reviews, 1998